<DOC>
	<DOCNO>NCT01678690</DOCNO>
	<brief_summary>Open-label , Phase 0 , dose-escalation study 3 successive cohort ( 3 subject per cohort ) , determine characterize plasma PK gemcitabine HCl oral formulation ( D07001-F4 ) administer Day 1 7 Days study follow-up . In addition , oral tolerability safety also assess 1-week period .</brief_summary>
	<brief_title>An Exploratory Study Gemcitabine Hydrochloride Oral Formulation ( D07001-F4 ) Subjects With Malignant Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Male female subject age 18 year old . 2 . Signed date informed consent form . 3 . Subjects malignancies histological pathologic confirmation clinically stable . 4 . History treatment least 1 cytotoxic chemotherapy regimen current malignancy . 5 . If subject receive cytotoxic chemotherapy within past 14 day , subject beyond nadir white blood cell platelet count . 6 . At least 28 day elapse since subject 's prior radiotherapy major surgery ( exclude diagnostic biopsy venous access device placement ) . 7 . World Health Organization ( WHO ) performance status 0 2 8 . Subject ANC ≥1500 cells/mm³ , platelet count ≥ 100,000 cells/mm³ , hemoglobin ≥ 9 g/dL . 9 . Subject adequate liver function demonstrate transaminase within normal limit ( aspartate transaminase alanine transaminase ) , total bilirubin ≤ 1.5 mg/dL ( unless due Gilbert 's syndrome ) , albumin ≥ 2.5 g/dL , international normalize ratio [ INR ] &lt; 1.5 ) . 10 . Subject adequate renal function : serum creatinine ≤ 1.5 x upper limit normal . 11 . Subject life expectancy &gt; 24 week . 12 . If woman childbearing potential , subject negative pregnancy test breastfeeding . 13 . If woman childbearing potential , subject use medically acceptable form birth control prior screen duration study participation 1 month end study . 14 . Subject willing comply protocolrequired visit schedule visit requirement provide write informed consent . 1 . Subject rapidly progressive disease rapid clinical deterioration assess Investigator . 2 . Subject receive fulldose ( therapeutic ) anticoagulation therapy . 3 . Subject receive concomitant radiotherapy . 4 . Subject intolerant allergic know hypersensitivity gemcitabine . 5 . Subject clinically significant cardiovascular disease ( example : uncontrolled hypertension , unstable angina , congestive heart failure , New York Heart Association Grade 2 great ) . 6 . Subject uncontrolled serious cardiac arrhythmia . 7 . Subject know active brain metastasis , leptomeningeal metastasis . 8 . Subject history drug alcohol abuse within last year . 9 . Subject document cerebrovascular disease . 10 . Subject seizure disorder control medication . 11 . Subject receive investigational agent within 30 day screen . 12 . Subject receive systemic treatment infection within 14 day screen . 13 . Subject know human immunodeficiency virus infection viral hepatitis . 14 . Subject serious medical condition , investigator 's medical opinion , would preclude safe participation clinical trial . 15 . Subject gastrointestinal disease prior gastrointestinal surgery may interfere adequate oral therapy absorption .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>